BiotechTube

SAL003 140 mg + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia

Conditions

Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia

Trial Timeline

Dec 19, 2023 → Jun 30, 2025

NCT ID
NCT07253584

About SAL003 140 mg + Placebo

SAL003 140 mg + Placebo is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT07253584. Target conditions include Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia.

What happened to similar drugs?

2 of 4 similar drugs in Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia were approved

Approved (2) Terminated (0) Active (2)
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07253584Phase 3Completed
NCT07295418Phase 3Completed

Competing Products

5 competing products in Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia

See all competitors
ProductCompanyStageHype Score
Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
39
atorvastatin + atorvastatin + atorvastatinPfizerApproved
43
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SLN360 + PlaceboMedpacePhase 1
26
Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3
34